Lv3
234 积分 2025-01-16 加入
Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What’s the Current Status?
5天前
已完结
Efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed immune thrombocytopenia
16天前
已完结
Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function
18天前
已完结
Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study
23天前
已完结
From covalent to reversible: the expanding role of BTK inhibitors in chronic lymphocytic leukemia
25天前
已完结
The global epidemiology of acute myeloid leukaemia
1个月前
已完结
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
1个月前
已完结
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial
1个月前
已完结
Sustained response off treatment in eltrombopag for children with persistent/chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China
1个月前
已完结
Long‐term eltrombopag in children with chronic immune thrombocytopenia: A single‐centre extended real‐life observational study in China
1个月前
已完结
HYDRA: A Multi-Level Hierarchy-Driven Approach for Robust Anomaly Detection in Time Series
皖公网安备34019202002308
